EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

SGLT2 inhibitor use in the management of feline diabetes mellitus

Audrey K Cook iD, Ellen Behrend iD

Journal of Veterinary Pharmacology and Therapeutics · 2025-01 · 48 (S1) · 19-30

DOI: 10.1111/jvp.13466 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Veterinary Pharmacology and Therapeutics, online erschienen am 02.07.2024. Verfasst von Audrey K Cook und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Small Animal Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, Texas, U…. Hauptthemen laut MEDLINE: Cat Diseases, Sodium-Glucose Transporter 2 Inhibitors, Hypoglycemic Agents, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors are routinely used in the management of human type 2 diabetes and have been shown to effectively mitigate hyperglycemia and reduce the risks of cardiovascular and renal compromise. Two SGLT2 inhibitors, namely bexagliflozin and velagliflozin, were recently FDA approved for the treatment of uncomplicated feline diabetes mellitus. These oral hypoglycemic agents are a suitable option for many newly diagnosed cats, with rapid improvements in glycemic control and clinical signs. Suitable candidates must have some residual β‐cell function, as some endogenous insulin production is required to prevent ketosis. Appropriate patient selection and monitoring are necessary, and practitioners should be aware of serious complications such as euglycemic diabetic ketoacidosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cat DiseasesSodium-Glucose Transporter 2 InhibitorsHypoglycemic AgentsDiabetes Mellitus, Type 2Diabetes MellitusAnimalsCats

Stichwörter der Autor:innen

bexagliflozincatdiabetesvelagliflozin

Substanzen

Sodium-Glucose Transporter 2 InhibitorsHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Small Animal Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, Texas, USA.
  • Veterinary Information Network, Davis, California, USA.

ORCID-Profile: Audrey K Cook, Ellen Behrend

Zitieren

APA

Cook, A. K., & Behrend, E. (2025). SGLT2 inhibitor use in the management of feline diabetes mellitus. Journal of Veterinary Pharmacology and Therapeutics, 48(S1), 19-30. https://doi.org/10.1111/jvp.13466

Vancouver

Cook AK, Behrend E. SGLT2 inhibitor use in the management of feline diabetes mellitus. Journal of Veterinary Pharmacology and Therapeutics. 2025;48(S1):19-30. doi:10.1111/jvp.13466

BibTeX
@article{Cook2025,
  author = {Cook, Audrey K and Behrend, Ellen},
  title = {SGLT2 inhibitor use in the management of feline diabetes mellitus},
  journal = {Journal of Veterinary Pharmacology and Therapeutics},
  year = {2025},
  volume = {48},
  number = {S1},
  pages = {19--30},
  doi = {10.1111/jvp.13466}
}
Kostenlos starten →